Sichuan Kelun-Biotech SKB500 Study Results
Analysis based on 6 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026
The positive first-in-human study results for SKB500, a novel B7-H3 ADC developed by Sichuan Kelun-Biotech Biopharmaceutical, are expected to generate significant investor interest in the biotechnology and pharmaceutical sectors. This could lead to an increase in the stock price of Sichuan Kelun-Biotech Biopharmaceutical and its parent company, Sichuan Kelun Pharmaceutical, as the drug shows promising efficacy and a favorable safety profile for advanced solid tumors, particularly small cell lung cancer.
Sichuan Kelun-Biotech Biopharmaceutical announced the positive first-in-human study results for its novel B7-H3 ADC SKB500 at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago, United States. Professor Liu Haifeng from Jilin Provincial Cancer Hospital presented the data, which showed broad-spectrum antitumor activity across multiple solid tumor types, including small cell lung cancer (SCLC), esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC), and pancreatic ductal adenocarcinoma (PDAC). Notably, in SCLC patients, the objective response rate (ORR) was 65.0%. The study also demonstrated a favorable safety profile for SKB500, particularly at the 12 mg/kg dose, with a low incidence of severe adverse events and no treatment-related deaths. These findings lay a solid foundation for further clinical development, with a Phase II exploratory study already underway in China for extensive-stage SCLC.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard